December 25th, 2023
Orphan Drug designation for Borofalan (10B) (SPM-011) as treatment of Cutaneous Angiosarcoma
Angiosarcoma is a kind of cancer that is derived from vascular endothelial cell……
BNCT
December 13th, 2023
Stella Pharma, Mitsubishi Chemical Group, and the University of Tokyo conclude Joint Research Agreement—Accelerating practical application of polyvinyl alcohol (PVA) for boron neutron capture therapy (BNCT)—
Stella Pharma Corporation , Mitsubishi Chemical Corporation of the Mitsubishi C……
December 6th, 2023
Encounter with Director of Cancer Research Center of Lyon, and Team of Centre Léon Bérard at French Embassy
Business France Japan Office of the French Embassy in Japan engages in building……
June 24th, 2022
Notice Regarding Our First Overseas Introduction of BNCT in the Hainan Medical Tourism Pilot Zone, China
Sumitomo Heavy Industries, Ltd. and STELLA PHARMA CORPORATION have respectively……
February 18th, 2022
“Destroying Cancer with Boron and Neutrons” will be on NHK WORLD-JAPAN
Japan's public media organization NHK (Japan Broadcasting Corporation) will bro……
October 21st, 2021
Interview published on Science Japan, online magazine| Japan’s “Fifth Cancer Treatment,” BNCT, Finally Off the Ground
Here is a featured story on BNCT (Boron Neutron Capture Therapy) boron drug dev……
June 23rd, 2021
The phase II study of recurrent glioblastoma in Japan has published in “Neuro-Oncology Advances”
The title is “Accelerator-based BNCT for patients with recurrent glioblastoma: ……
December 9th, 2020
The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology”
The title is "Boron neutron capture therapy using cyclotron-based epithermal ne……
